Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant mycobacterium tuberculosis in rural china

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 8, 2013, Pages 3857-3863

  Hu, Yi ^a   Hoffner, Sven ^b   Wu, Linlin ^a   Zhao, Qi ^a   Jiang, Weili ^a   Xu, Biao ^a  

^a FUDAN UNIVERSITY   (China)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIUM ISOLATE; CHINA; CONTROLLED STUDY; DNA POLYMORPHISM; DNA SEQUENCE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RURAL AREA; SPUTUM SMEAR; STRUCTURED QUESTIONNAIRE; THORAX RADIOGRAPHY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTITUBERCULAR AGENTS; CAPREOMYCIN; CHINA; CROSS-SECTIONAL STUDIES; DNA GYRASE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; KANAMYCIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RURAL POPULATION; YOUNG ADULT;

EID: 84880278957     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00102-13     Document Type: Article

References (34)

1. World Health Organization. 2010. Tuberculosis global facts. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2012. Global tuberculosis control report 2012. World Health Organization, Geneva, Switzerland.
3. Han T. 2006. Effectiveness of standard short-course chemotherapy for treating tuberculosis and the impact of drug resistance on its outcome. Int. J. Evid. Based Healthc. 4:101-117.
4. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med. 366:2161-2170.
5. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, Deriemer K, Mei J, Gao Q. 2009. Transmission ofMDRandXDRtuberculosis in Shanghai, China. PLoS One 4:e4370. doi:10.1371/journal.pone.0004370.
6. Li X, Wang H, Jing H, Wang Y, Yu C, Wang J, Liu Z, Graviss EA, Ma X. 2012. Population-based surveillance of extensively drug-resistant tuberculosis in Shandong Province, China. Int. J. Tuberc. Lung Dis. 16:612-614.
7. Liu CH, Li HM, Li L, Hu YL, Wang Q, Yang N, Wang S, Zhu B. 2011. Anti-tuberculosis drug resistance patterns and trends in a tuberculosis referral hospital, 1997-2009. Epidemiol. Infect. 139:1909-1918.
8. Almeida Da Silva PE, Palomino JC. 2011. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66:1417-1430.
9. Zhang Y, Yew WW. 2009. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13:1320-1330.
10. Zhao X, Xu C, Domagala J, Drlica K. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. U. S. A. 94:13991-13996.
11. Alangaden GJ, Kreiswirth BN, Aouad A, Khetarpal M, Igno FR, Moghazeh SL, Manavathu EK, Lerner SA. 1998. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42:1295-1297.
12. Wilbrink B, van der Heijden IM, Schouls LM, van Embden JD, Hazes JM, Breedveld FC, Tak PP. 1998. Detection of bacterial DNA in joint samples from patients with undifferentiated arthritis and reactive arthritis, using polymerase chain reaction with universal 16S ribosomal RNA primers. Arthritis Rheum. 41:535-543.
13. Johansen SK, Maus CE, Plikaytis BB, Douthwaite S. 2006. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2=-Omethylations in 16S and 23S rRNAs. Mol. Cell 23:173-182.
14. Maus CE, Plikaytis BB, Shinnick TM. 2005. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:571-577.
15. Ahmed N, Alam M, Rao KR, Kauser F, Kumar NA, Qazi NN, Sangal V, Sharma VD, Das R, Katoch VM, Murthy KJ, Suneetha S, Sharma SK, Sechi LA, Gilman RH, Hasnain SE. 2004. Molecular genotyping of a large, multicentric collection of tubercle bacilli indicates geographical partitioning of strain variation and has implications for global epidemiology of Mycobacterium tuberculosis. J. Clin. Microbiol. 42:3240-3247.
16. Ramazanzadeh R, Farnia P, Amirmozafari N, Ghazi F, Ghadertotonchi Z, Kamran J, Mohammadi F, Mirsaedi M, Masjedi M. 2006. Comparison between molecular epidemiology, geographical regions and drug resistance in Mycobacterium tuberculosis strains isolated from Iranian and Afghan patients. Chemotherapy 52:316-320.
17. Kent PT, Kubica GP. 1985. Public health mycobacteriology: a guide for the level III laboratory. U.S. Department of Health and Human Services/ Public Health Service/Centers for Disease Control, Atlanta, GA.
18. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ. 41:21-43.
19. World Health Organization. 2006. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly. Epidemiol. Rec. 81: 430-432.
20. Banerjee R, Allen J, Westenhouse J, Oh P, Elms W, Desmond E, Nitta A, Royce S, Flood J. 2008. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin. Infect. Dis. 47:450-457.
21. Engstrom A, Perskvist N, Werngren J, Hoffner SE, Jureen P. 2011. Comparison of clinical isolates and in vitro selected mutants reveals that tlyA is not a sensitive genetic marker for capreomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 66:1247-1254.
22. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rusch-Gerdes S, Niemann S. 2009. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob. Agents Chemother. 53:3353-3356.
23. USCDC. 2007. Extensively drug-resistant tuberculosis-United States, 1993-2006. MMWR Morb. Mortal. Wkly. Rep. 56:250-253.
24. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, Skenders G, Holtz TH. 2010. Treatment outcome of multidrug/ extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur. Respir. J. 36:584-593.
25. Kliiman K, Altraja A. 2009. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann. Intern. Med. 150:766-775.
26. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. 2010. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 48:1683-1689.
27. Hillemann D, Rusch-Gerdes S, Richter E. 2009. Feasibility of the Geno-Type MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 47:1767-1772.
28. Lin SY, Desmond E, Bonato D, Gross W, Siddiqi S. 2009. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J. Clin. Microbiol. 47:3630-3634.
29. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh Chau N, Chinh NT, Farrar J, Caws M. 2010. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J. Clin. Microbiol. 48:2934-2939.
30. Hegde SS, Vetting MW, Roderick SL, Mitchenall LA, Maxwell A, Takiff HE, Blanchard JS. 2005. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA. Science 308:1480-1483.
31. Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, Rastogi N. 2008. Molecular characterization of ofloxacinresistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52:2937-2939.
32. Pasca MR, Guglierame P, Arcesi F, Bellinzoni M, De Rossi E, Riccardi G. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178.
33. Zaunbrecher MA, Sikes RD, Jr, Metchock B, Shinnick TM, Posey JE. 2009. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 106:20004-20009.
34. Maus CE, Plikaytis BB, Shinnick TM. 2005. Molecular analysis of crossresistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192-3197.